These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 1312588

  • 1. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
    Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH.
    J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL.
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [Abstract] [Full Text] [Related]

  • 3. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG.
    Cancer Res; 1993 Mar 01; 53(5):1032-6. PubMed ID: 8439950
    [Abstract] [Full Text] [Related]

  • 4. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC.
    J Clin Oncol; 1996 Apr 01; 14(4):1224-35. PubMed ID: 8648378
    [Abstract] [Full Text] [Related]

  • 5. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
    Kakolyris S, Kouroussis C, Souglakos J, Mavroudis D, Agelaki S, Kalbakis K, Androulakis N, Vardakis N, Vamvakas L, Georgoulias V.
    Oncology; 2001 Apr 01; 61(4):265-70. PubMed ID: 11721172
    [Abstract] [Full Text] [Related]

  • 6. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, Rock MK, Donehower RC.
    Cancer Res; 1994 Jan 15; 54(2):427-36. PubMed ID: 8275479
    [Abstract] [Full Text] [Related]

  • 7. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    Rowinsky EK, Johnson TR, Geyer CE, Hammond LA, Eckhardt SG, Drengler R, Smetzer L, Coyle J, Rizzo J, Schwartz G, Tolcher A, Von Hoff DD, De Jager RL.
    J Clin Oncol; 2000 Sep 15; 18(17):3151-63. PubMed ID: 10963644
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J.
    Semin Oncol; 1997 Feb 15; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [Abstract] [Full Text] [Related]

  • 9. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
    Creemers GJ, Gerrits CJ, Eckardt JR, Schellens JH, Burris HA, Planting AS, Rodriguez GI, Loos WJ, Hudson I, Broom C, Verweij J, Von Hoff DD.
    J Clin Oncol; 1997 Mar 15; 15(3):1087-93. PubMed ID: 9060549
    [Abstract] [Full Text] [Related]

  • 10. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
    Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ.
    J Clin Oncol; 1994 Mar 15; 12(3):553-9. PubMed ID: 8120553
    [Abstract] [Full Text] [Related]

  • 11. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
    Wall JG, Burris HA, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G.
    Anticancer Drugs; 1992 Aug 15; 3(4):337-45. PubMed ID: 1330081
    [Abstract] [Full Text] [Related]

  • 12. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.
    J Clin Oncol; 1995 Jan 15; 13(1):210-21. PubMed ID: 7799022
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    O'Reilly S, Fleming GF, Barker SD, Walczak JR, Bookman MA, McGuire WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK.
    J Clin Oncol; 1997 Jan 15; 15(1):177-86. PubMed ID: 8996140
    [Abstract] [Full Text] [Related]

  • 14. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
    Eckhardt SG, Baker SD, Eckardt JR, Burke TG, Warner DL, Kuhn JG, Rodriguez G, Fields S, Thurman A, Smith L, Rothenberg ML, White L, Wissel P, Kunka R, DePee S, Littlefield D, Burris HA, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 1998 Mar 15; 4(3):595-604. PubMed ID: 9533526
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G, Briasoulis E, Karavassilis V, Mauri D, Tzamakou E, Rammou D, Pavlidis N.
    Chemotherapy; 2005 May 15; 51(2-3):154-61. PubMed ID: 15886476
    [Abstract] [Full Text] [Related]

  • 16. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
    Boige V, Raymond E, Faivre S, Gatineau M, Meely K, Mekhaldi S, Pautier P, Ducreux M, Rixe O, Armand JP.
    J Clin Oncol; 2000 Dec 01; 18(23):3986-92. PubMed ID: 11099328
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Verschraegen CF, Kudelka AP, Hu W, Vincent M, Kavanagh JJ, Loyer E, Bastien L, Duggal A, De Jager R.
    Cancer Chemother Pharmacol; 2004 Jan 01; 53(1):1-7. PubMed ID: 14586557
    [Abstract] [Full Text] [Related]

  • 18. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
    van Warmerdam LJ, ten Bokkel Huinink WW, Rodenhuis S, Koier I, Davies BE, Rosing H, Maes RA, Beijnen JH.
    J Clin Oncol; 1995 Jul 01; 13(7):1768-76. PubMed ID: 7602366
    [Abstract] [Full Text] [Related]

  • 19. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
    Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC.
    J Clin Oncol; 1996 Dec 01; 14(12):3074-84. PubMed ID: 8955652
    [Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
    Burris HA, Awada A, Kuhn JG, Eckardt JR, Cobb PW, Rinaldi DA, Fields S, Smith L, Von Hoff DD.
    Anticancer Drugs; 1994 Aug 01; 5(4):394-402. PubMed ID: 7949242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.